Therapeutic Applications of Curcumin Nanoformulations

AAPS Journal

Volumn 17, Issue 6, 2015, Pages 1341-1356

  Yallapu, Murali M ^a   Nagesh, Prashanth K Bhusetty ^a   Jaggi, Meena ^a   Chauhan, Subhash C ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

cancer; curcumin; drug delivery; nanoparticles; nanotechnology

Indexed keywords

C REACTIVE PROTEIN; CURCUMIN; CYCLODEXTRIN DERIVATIVE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DEMETHOXYCURCUMIN; DENDRIMER; DIDEMETHOXYCURCUMIN; DOXORUBICIN; GOLD NANOPARTICLE; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPID NANOPARTICLE; LIPOPOLYSACCHARIDE; LIPOSOME; MAGNETIC NANOPARTICLE; NANOCARRIER; NANOGEL; NANOPARTICLE; NITRIC OXIDE SYNTHASE; PLACEBO; POLYGLACTIN; POLYMER; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT;

ALBUMINURIA; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTHRITIS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN DISEASE; CANCER INHIBITION; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CHEMICAL COMPOSITION; CORNEA NEOVASCULARIZATION; CYSTIC FIBROSIS; DEGENERATIVE DISEASE; DIABETIC NEUROPATHY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DISPERSION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG TOLERABILITY; ENCAPSULATION; GLOMERULUS FILTRATION RATE; HEART DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHILICITY; IC50; INFLAMMATION; KIDNEY DISEASE; LIPOPHILICITY; LIVER DISEASE; LOW DRUG DOSE; MALARIA; MALIGNANT NEOPLASTIC DISEASE; MIDDLE CEREBRAL ARTERY OCCLUSION; NANOTECHNOLOGY; NEUROPROTECTION; NEUROTOXICITY; NITROSATIVE STRESS; NONHUMAN; OSTEOPOROSIS; OXIDATIVE STRESS; PARTICLE SIZE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; RHEUMATOID ARTHRITIS; SCALE UP; SINGLE DRUG DOSE; SKIN DISEASE; WOUND HEALING; ANIMAL; CHEMISTRY; MEDICINAL CHEMISTRY; NEOPLASMS; NERVOUS SYSTEM DISEASES; PROCEDURES; TRENDS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHEMISTRY, PHARMACEUTICAL; CURCUMIN; DRUG DELIVERY SYSTEMS; HUMANS; NANOTECHNOLOGY; NEOPLASMS; NERVOUS SYSTEM DISEASES;

EID: 84945489189     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-015-9811-z     Document Type: Article

References (135)

1. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol. 2007;595:1–75. doi:10.1007/978-0-387-46401-5_1.
2. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: a short review. Life Sci. 2006;78(18):2081–7. doi:10.1016/j.lfs.2005.12.007.
3. Trujillo J, Chirino YI, Molina-Jijon E, Anderica-Romero AC, Tapia E, Pedraza-Chaverri J. Renoprotective effect of the antioxidant curcumin: recent findings. Redox Biol. 2013;1:448–56. doi:10.1016/j.redox.2013.09.003.
4. Burgos-Moron E, Calderon-Montano JM, Salvador J, Robles A, Lopez-Lazaro M. The dark side of curcumin. Int J Cancer J Int du Cancer. 2010;126(7):1771–5. doi:10.1002/ijc.24967.
5. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–18. doi:10.1021/mp700113r.
6. Yang CS, Sang S, Lambert JD, Lee MJ. Bioavailability issues in studying the health effects of plant polyphenolic compounds. Mol Nutr Food Res. 2008;52 Suppl 1:S139–51. doi:10.1002/mnfr.200700234.
7. Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov Today. 2012;17(1–2):71–80. doi:10.1016/j.drudis.2011.09.009.
8. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013;15(1):195–218. doi:10.1208/s12248-012-9432-8.
9. Gupta SC, Sung B, Kim JH, Prasad S, Li S, Aggarwal BB. Multitargeting by turmeric, the golden spice: from kitchen to clinic. Mol Nutr Food Res. 2013;57(9):1510–28. doi:10.1002/mnfr.201100741.
10. Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanomedicine: a road to cancer therapeutics. Curr Pharm Des. 2013;19(11):1994–2010.
11. Ghalandarlaki N, Alizadeh AM, Ashkani-Esfahani S. Nanotechnology-applied curcumin for different diseases therapy. BioMed Res Int. 2014;2014:394264. doi:10.1155/2014/394264.
12. Naksuriya O, Okonogi S, Schiffelers RM, Hennink WE. Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials. 2014;35(10):3365–83. doi:10.1016/j.biomaterials.2013.12.090.
13. Bansal SS, Goel M, Aqil F, Vadhanam MV, Gupta RC. Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev Res. 2011;4(8):1158–71. doi:10.1158/1940-6207.CAPR-10-0006.
14. Sun M, Su X, Ding B, He X, Liu X, Yu A, et al. Advances in nanotechnology-based delivery systems for curcumin. Nanomedicine. 2012;7(7):1085–100. doi:10.2217/nnm.12.80.
15. Yallapu MM, Ebeling MC, Jaggi M, Chauhan SC. Plasma proteins interaction with curcumin nanoparticles: implications in cancer therapeutics. Curr Drug Metab. 2013;14(4):504–15.
16. Flora G, Gupta D, Tiwari A. Nanocurcumin: a promising therapeutic advancement over native curcumin. Crit Rev Ther Drug Carrier Syst. 2013;30(4):331–68.
17. Lee WH, Loo CY, Young PM, Traini D, Mason RS, Rohanizadeh R. Recent advances in curcumin nanoformulation for cancer therapy. Expert Opin Drug Deliv. 2014;11(8):1183–201. doi:10.1517/17425247.2014.916686.
18. Kanai M, Imaizumi A, Otsuka Y, Sasaki H, Hashiguchi M, Tsujiko K, et al. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother Pharmacol. 2012;69(1):65–70. doi:10.1007/s00280-011-1673-1.
19. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9(8):615–27. doi:10.1038/nrd2591.
20. Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014;13(11):813–27. doi:10.1038/nrd4333.
21. Gunasekaran T, Haile T, Nigusse T, Dhanaraju MD. Nanotechnology: an effective tool for enhancing bioavailability and bioactivity of phytomedicine. Asian Pac J Trop Biomed. 2014;4 Suppl 1:S1–7. doi:10.12980/APJTB.4.2014C980.
22. Das M, Sahoo SK. Folate decorated dual drug loaded nanoparticle: role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance. PLoS One. 2012;7(3), e32920. doi:10.1371/journal.pone.0032920.
23. Scarano W, Souza P, Stenzel MH. Dual-drug delivery of curcumin and platinum drugs in polymeric micelles enhances the synergistic effects: a double act for the treatment of multidrug-resistant cancer. Biomater Sci. 2015;3:163–74.
24. Tiyaboonchai W, Tungpradit W, Plianbangchang P. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int J Pharm. 2007;337(1–2):299–306. doi:10.1016/j.ijpharm.2006.12.043.
25. Mulik R, Mahadik K, Paradkar A. Development of curcuminoids loaded poly(butyl) cyanoacrylate nanoparticles: physicochemical characterization and stability study. Eur J Pharm Sci: Off J Eur Fed Pharm Sci. 2009;37(3–4):395–404. doi:10.1016/j.ejps.2009.03.009.
26. Onoue S, Takahashi H, Kawabata Y, Seto Y, Hatanaka J, Timmermann B, et al. Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability. J Pharm Sci. 2010;99(4):1871–81. doi:10.1002/jps.21964.
27. Yallapu MM, Jaggi M, Chauhan SC. beta-Cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells. Colloids Surf B: Biointerfaces. 2010;79(1):113–25. doi:10.1016/j.colsurfb.2010.03.039.
28. Yallapu MM, Jaggi M, Chauhan SC. Poly(beta-cyclodextrin)/curcumin self-assembly: a novel approach to improve curcumin delivery and its therapeutic efficacy in prostate cancer cells. Macromol Biosci. 2010;10(10):1141–51. doi:10.1002/mabi.201000084.
29. Ranjan AP, Mukerjee A, Helson L, Vishwanatha JK. Scale up, optimization and stability analysis of curcumin C3 complex-loaded nanoparticles for cancer therapy. J Nanobiotechnology. 2012;10:38. doi:10.1186/1477-3155-10-38.
30. Yallapu MM, Khan S, Maher DM, Ebeling MC, Sundram V, Chauhan N, et al. Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. Biomaterials. 2014;35(30):8635–48. doi:10.1016/j.biomaterials.2014.06.040.
31. Nagahama K, Sano Y, Kumano T. Anticancer drug-based multifunctional nanogels through self-assembly of dextran-curcumin conjugates toward cancer theranostics. Bioorg Med Chem Lett. 2015. doi:10.1016/j.bmcl.2015.04.062.
32. Zou P, Helson L, Maitra A, Stern ST, McNeil SE. Polymeric curcumin nanoparticle pharmacokinetics and metabolism in bile duct cannulated rats. Mol Pharm. 2013;10(5):1977–87. doi:10.1021/mp4000019.
33. Chiu SS, Lui E, Majeed M, Vishwanatha JK, Ranjan AP, Maitra A, et al. Differential distribution of intravenous curcumin formulations in the rat brain. Anticancer Res. 2011;31(3):907–11.
34. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A, et al. Polymeric nanoparticle-encapsulated curcumin (“nanocurcumin”): a novel strategy for human cancer therapy. J Nanobiotechnology. 2007;5:3. doi:10.1186/1477-3155-5-3.
35. Lim KJ, Bisht S, Bar EE, Maitra A, Eberhart CG. A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol Ther. 2011;11(5):464–73.
36. Chun YS, Bisht S, Chenna V, Pramanik D, Yoshida T, Hong SM, et al. Intraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCurc) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model: implications for breast cancer chemoprevention in at-risk populations. Carcinogenesis. 2012;33(11):2242–9. doi:10.1093/carcin/bgs248.
37. Bisht S, Mizuma M, Feldmann G, Ottenhof NA, Hong SM, Pramanik D, et al. Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer. Mol Cancer Ther. 2010;9(8):2255–64. doi:10.1158/1535-7163.MCT-10-0172.
38. Bisht S, Khan MA, Bekhit M, Bai H, Cornish T, Mizuma M, et al. A polymeric nanoparticle formulation of curcumin (NanoCurc) ameliorates CCl4-induced hepatic injury and fibrosis through reduction of pro-inflammatory cytokines and stellate cell activation. Lab Investig J Tech Methods Pathol. 2011;91(9):1383–95. doi:10.1038/labinvest.2011.86.
39. Shutava TG, Balkundi SS, Vangala P, Steffan JJ, Bigelow RL, Cardelli JA, et al. Layer-by-layer-coated gelatin nanoparticles as a vehicle for delivery of natural polyphenols. ACS Nano. 2009;3(7):1877–85. doi:10.1021/nn900451a.
40. Prajakta D, Ratnesh J, Chandan K, Suresh S, Grace S, Meera V, et al. Curcumin loaded pH-sensitive nanoparticles for the treatment of colon cancer. J Biomed Nanotechnol. 2009;5(5):445–55.
41. Yallapu MM, Othman SF, Curtis ET, Gupta BK, Jaggi M, Chauhan SC. Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy. Biomaterials. 2011;32(7):1890–905. doi:10.1016/j.biomaterials.2010.11.028.
42. Yallapu MM, Othman SF, Curtis ET, Bauer NA, Chauhan N, Kumar D, et al. Curcumin-loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications. Int J Nanomedicine. 2012;7:1761–79. doi:10.2147/IJN.S29290.
43. Yallapu MM, Foy SP, Jain TK, Labhasetwar V. PEG-functionalized magnetic nanoparticles for drug delivery and magnetic resonance imaging applications. Pharm Res. 2010;27(11):2283–95. doi:10.1007/s11095-010-0260-1.
44. Yallapu MM, Chauhan N, Othman SF, Khalilzad-Sharghi V, Ebeling MC, Khan S, et al. Implications of protein corona on physico-chemical and biological properties of magnetic nanoparticles. Biomaterials. 2015;46:1–12. doi:10.1016/j.biomaterials.2014.12.045.
45. Manju S, Sreenivasan K. Gold nanoparticles generated and stabilized by water soluble curcumin-polymer conjugate: blood compatibility evaluation and targeted drug delivery onto cancer cells. J Colloid Interface Sci. 2012;368(1):144–51. doi:10.1016/j.jcis.2011.11.024.
46. Singh DK, Jagannathan R, Khandelwal P, Abraham PM, Poddar P. In situ synthesis and surface functionalization of gold nanoparticles with curcumin and their antioxidant properties: an experimental and density functional theory investigation. Nanoscale. 2013;5(5):1882–93. doi:10.1039/c2nr33776b.
47. Manju S, Sreenivasan K. Enhanced drug loading on magnetic nanoparticles by layer-by-layer assembly using drug conjugates: blood compatibility evaluation and targeted drug delivery in cancer cells. Langmuir: ACS J Surf Colloids. 2011;27(23):14489–96. doi:10.1021/la202470k.
48. Anwar M, Asfer M, Prajapati AP, Mohapatra S, Akhter S, Ali A, et al. Synthesis and in vitro localization study of curcumin-loaded SPIONs in a micro capillary for simulating a targeted drug delivery system. Int J Pharm. 2014;468(1–2):158–64. doi:10.1016/j.ijpharm.2014.04.038.
49. Chen W, Xu N, Xu L, Wang L, Li Z, Ma W, et al. Multifunctional magnetoplasmonic nanoparticle assemblies for cancer therapy and diagnostics (theranostics). Macromol Rapid Commun. 2010;31(2):228–36. doi:10.1002/marc.200900793.
50. Rao W, Zhang W, Poventud-Fuentes I, Wang Y, Lei Y, Agarwal P, et al. Thermally responsive nanoparticle-encapsulated curcumin and its combination with mild hyperthermia for enhanced cancer cell destruction. Acta Biomater. 2014;10(2):831–42.
51. Wang H, Yi J, Mukherjee S, Banerjee P, Zhou S. Magnetic/NIR-thermally responsive hybrid nanogels for optical temperature sensing, tumor cell imaging and triggered drug release. Nanoscale. 2014;6(21):13001–11. doi:10.1039/c4nr03748k.
52. Patra S, Roy E, Karfa P, Kumar S, Madhuri R, Sharma PK. Dual-responsive polymer coated superparamagnetic nanoparticle for targeted drug delivery and hyperthermia treatment. ACS Appl Mater Interfaces. 2015;7(17):9235–46. doi:10.1021/acsami.5b01786.
53. Sanoj Rejinold N, Thomas RG, Muthiah M, Chennazhi KP, Manzoor K, Park IK, et al. Anti-cancer, pharmacokinetics and tumor localization studies of pH-, RF- and thermo-responsive nanoparticles. Int J Biol Macromol. 2015;74:249–62. doi:10.1016/j.ijbiomac.2014.11.044.
54. Mulik RS, Monkkonen J, Juvonen RO, Mahadik KR, Paradkar AR. Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis. Int J Pharm. 2010;398(1–2):190–203. doi:10.1016/j.ijpharm.2010.07.021.
55. Abouzeid AH, Patel NR, Sarisozen C, Torchilin VP. Transferrin-targeted polymeric micelles co-loaded with curcumin and paclitaxel: efficient killing of paclitaxel-resistant cancer cells. Pharm Res. 2014;31(8):1938–45. doi:10.1007/s11095-013-1295-x.
56. Pillai JJ, Thulasidasan AK, Anto RJ, Chithralekha DN, Narayanan A, Kumar GS. Folic acid conjugated cross-linked acrylic polymer (FA-CLAP) hydrogel for site specific delivery of hydrophobic drugs to cancer cells. J Nanobiotechnology. 2014;12:25. doi:10.1186/1477-3155-12-25.
57. Chen D, Lian S, Sun J, Liu Z, Zhao F, Jiang Y, et al. Design of novel multifunctional targeting nano-carrier drug delivery system based on CD44 receptor and tumor microenvironment pH condition. Drug Deliv. 2014:1–6. doi: 10.3109/10717544.2014.917130.
58. Fang JH, Lai YH, Chiu TL, Chen YY, Hu SH, Chen SY. Magnetic core-shell nanocapsules with dual-targeting capabilities and co-delivery of multiple drugs to treat brain gliomas. Adv Healthc Mater. 2014;3(8):1250–60. doi:10.1002/adhm.201300598.
59. Punfa W, Yodkeeree S, Pitchakarn P, Ampasavate C, Limtrakul P. Enhancement of cellular uptake and cytotoxicity of curcumin-loaded PLGA nanoparticles by conjugation with anti-P-glycoprotein in drug resistance cancer cells. Acta Pharmacol Sin. 2012;33(6):823–31. doi:10.1038/aps.2012.34.
60. Thamake SI, Raut SL, Ranjan AP, Gryczynski Z, Vishwanatha JK. Surface functionalization of PLGA nanoparticles by non-covalent insertion of a homo-bifunctional spacer for active targeting in cancer therapy. Nanotechnology. 2011;22(3):035101. doi:10.1088/0957-4484/22/3/035101.
61. Yu Y, Zhang X, Qiu L. The anti-tumor efficacy of curcumin when delivered by size/charge-changing multistage polymeric micelles based on amphiphilic poly(beta-amino ester) derivates. Biomaterials. 2014;35(10):3467–79. doi:10.1016/j.biomaterials.2013.12.096.
62. Wang YJ, Lin HY, Wu CH, Liu DM. Forming of demethoxycurcumin nanocrystallite-chitosan nanocarrier for controlled low dose cellular release for inhibition of the migration of vascular smooth muscle cells. Mol Pharm. 2012;9(8):2268–79. doi:10.1021/mp300150q.
63. Carlson LJ, Cote B, Alani AW, Rao DA. Polymeric micellar co-delivery of resveratrol and curcumin to mitigate in vitro doxorubicin-induced cardiotoxicity. J Pharm Sci. 2014;103(8):2315–22. doi:10.1002/jps.24042.
64. Pramanik D, Campbell NR, Das S, Gupta S, Chenna V, Bisht S, et al. A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy. Oncotarget. 2012;3(6):640–50.
65. Deveza L, Choi J, Yang F. Therapeutic angiogenesis for treating cardiovascular diseases. Theranostics. 2012;2(8):801–14. doi:10.7150/thno.4419.
66. Ding Q, Niu T, Yang Y, Guo Q, Luo F, Qian Z. Preparation of curcumin-loaded poly(ester amine) nanoparticles for the treatment of anti-angiogenesis. J Biomed Nanotechnol. 2014;10(4):632–41.
67. Re F, Cambianica I, Zona C, Sesana S, Gregori M, Rigolio R, et al. Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood–brain barrier model. Nanomedicine. 2011;7(5):551–9. doi:10.1016/j.nano.2011.05.004.
68. Doggui S, Sahni JK, Arseneault M, Dao L, Ramassamy C. Neuronal uptake and neuroprotective effect of curcumin-loaded PLGA nanoparticles on the human SK-N-SH cell line. J Alzheimer’s Dis: JAD. 2012;30(2):377–92. doi:10.3233/JAD-2012-112141.
69. Le Droumaguet B, Nicolas J, Brambilla D, Mura S, Maksimenko A, De Kimpe L, et al. Versatile and efficient targeting using a single nanoparticulate platform: application to cancer and Alzheimer’s disease. ACS Nano. 2012;6(7):5866–79. doi:10.1021/nn3004372.
70. Mourtas S, Lazar AN, Markoutsa E, Duyckaerts C, Antimisiaris SG. Multifunctional nanoliposomes with curcumin-lipid derivative and brain targeting functionality with potential applications for Alzheimer disease. Eur J Med Chem. 2014;80:175–83. doi:10.1016/j.ejmech.2014.04.050.
71. Taylor M, Moore S, Mourtas S, Niarakis A, Re F, Zona C, et al. Effect of curcumin-associated and lipid ligand-functionalized nanoliposomes on aggregation of the Alzheimer’s Abeta peptide. Nanomedicine. 2011;7(5):541–50. doi:10.1016/j.nano.2011.06.015.
72. Lazar AN, Mourtas S, Youssef I, Parizot C, Dauphin A, Delatour B, et al. Curcumin-conjugated nanoliposomes with high affinity for Abeta deposits: possible applications to Alzheimer disease. Nanomedicine. 2013;9(5):712–21. doi:10.1016/j.nano.2012.11.004.
73. Mourtas S, Canovi M, Zona C, Aurilia D, Niarakis A, La Ferla B, et al. Curcumin-decorated nanoliposomes with very high affinity for amyloid-beta1-42 peptide. Biomaterials. 2011;32(6):1635–45. doi:10.1016/j.biomaterials.2010.10.027.
74. Ray B, Bisht S, Maitra A, Maitra A, Lahiri DK. Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc) in the neuronal cell culture and animal model: implications for Alzheimer’s disease. J Alzheimer’s Dis: JAD. 2011;23(1):61–77. doi:10.3233/JAD-2010-101374.
75. Mulik RS, Monkkonen J, Juvonen RO, Mahadik KR, Paradkar AR. ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model. Mol Pharm. 2010;7(3):815–25. doi:10.1021/mp900306x.
76. Palmal S, Maity AR, Singh BK, Basu S, Jana NR, Jana NR. Inhibition of amyloid fibril growth and dissolution of amyloid fibrils by curcumin-gold nanoparticles. Chemistry. 2014;20(20):6184–91. doi:10.1002/chem.201400079.
77. Kakkar V, Kaur IP. Evaluating potential of curcumin loaded solid lipid nanoparticles in aluminium induced behavioural, biochemical and histopathological alterations in mice brain. Food Chem Toxicol: Int J Published Br Ind Biol Res Assoc. 2011;49(11):2906–13. doi:10.1016/j.fct.2011.08.006.
78. Doggui S, Belkacemi A, Paka GD, Perrotte M, Pi R, Ramassamy C. Curcumin protects neuronal-like cells against acrolein by restoring Akt and redox signaling pathways. Mol Nutr Food Res. 2013;57(9):1660–70. doi:10.1002/mnfr.201300130.
79. Cheng KK, Chan PS, Fan S, Kwan SM, Yeung KL, Wang YX, et al. Curcumin-conjugated magnetic nanoparticles for detecting amyloid plaques in Alzheimer’s disease mice using magnetic resonance imaging (MRI). Biomaterials. 2015;44:155–72. doi:10.1016/j.biomaterials.2014.12.005.
80. Jaruszewski KM, Curran GL, Swaminathan SK, Rosenberg JT, Grant SC, Ramakrishnan S, et al. Multimodal nanoprobes to target cerebrovascular amyloid in Alzheimer’s disease brain. Biomaterials. 2014;35(6):1967–76. doi:10.1016/j.biomaterials.2013.10.075.
81. Marrache S, Dhar S. Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc Natl Acad Sci U S A. 2012;109(40):16288–93. doi:10.1073/pnas.1210096109.
82. Sandhir R, Yadav A, Mehrotra A, Sunkaria A, Singh A, Sharma S. Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington’s disease. Neruomol Med. 2014;16(1):106–18. doi:10.1007/s12017-013-8261-y.
83. Kakkar V, Mishra AK, Chuttani K, Kaur IP. Proof of concept studies to confirm the delivery of curcumin loaded solid lipid nanoparticles (C-SLNs) to brain. Int J Pharm. 2013;448(2):354–9. doi:10.1016/j.ijpharm.2013.03.046.
84. Ramalingam P, Ko YT. A validated LC-MS/MS method for quantitative analysis of curcumin in mouse plasma and brain tissue and its application in pharmacokinetic and brain distribution studies. J Chromatogr B Anal Technol Biomed Life Sci. 2014;969:101–8. doi:10.1016/j.jchromb.2014.08.009.
85. Ramalingam P, Ko YT. Enhanced oral delivery of curcumin from N-trimethyl chitosan surface-modified solid lipid nanoparticles: pharmacokinetic and brain distribution evaluations. Pharm Res. 2015;32(2):389–402. doi:10.1007/s11095-014-1469-1.
86. Ahmad N, Ahmad I, Umar S, Iqbal Z, Samim M, Ahmad FJ. PNIPAM nanoparticles for targeted and enhanced nose-to-brain delivery of curcuminoids: UPLC/ESI-Q-ToF-MS/MS-based pharmacokinetics and pharmacodynamic evaluation in cerebral ischemia model. Drug Deliv. 2014:1–20. doi: 10.3109/10717544.2014.941076.
87. Ahmad N, Umar S, Ashafaq M, Akhtar M, Iqbal Z, Samim M, et al. A comparative study of PNIPAM nanoparticles of curcumin, demethoxycurcumin, and bisdemethoxycurcumin and their effects on oxidative stress markers in experimental stroke. Protoplasma. 2013;250(6):1327–38. doi:10.1007/s00709-013-0516-9.
88. Kalani A, Kamat PK, Kalani K, Tyagi N. Epigenetic impact of curcumin on stroke prevention. Metab Brain Dis. 2015;30(2):427–35. doi:10.1007/s11011-014-9537-0.
89. Kakkar V, Muppu SK, Chopra K, Kaur IP. Curcumin loaded solid lipid nanoparticles: an efficient formulation approach for cerebral ischemic reperfusion injury in rats. Eur J Pharm Biopharm: Off J Arbeitsgemeinschaft fur Pharm Verfahrenstechnik eV. 2013;85(3 Pt A):339–45. doi:10.1016/j.ejpb.2013.02.005.
90. Singh AK, Jiang Y, Gupta S, Younus M, Ramzan M. Anti-inflammatory potency of nano-formulated puerarin and curcumin in rats subjected to the lipopolysaccharide-induced inflammation. J Med Food. 2013;16(10):899–911. doi:10.1089/jmf.2012.0049.
91. Beloqui A, Coco R, Memvanga PB, Ucakar B, des Rieux A, Preat V. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease. Int J Pharm. 2014;473(1–2):203–12. doi:10.1016/j.ijpharm.2014.07.009.
92. Shukla P, Dwivedi P, Gupta PK, Mishra PR. Optimization of novel tocopheryl acetate nanoemulsions for parenteral delivery of curcumin for therapeutic intervention of sepsis. Expert Opin Drug Deliv. 2014;11(11):1697–712. doi:10.1517/17425247.2014.932769.
93. Sun D, Zhuang X, Xiang X, Liu Y, Zhang S, Liu C, et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther: J Am Soc Gene Ther. 2010;18(9):1606–14. doi:10.1038/mt.2010.105.
94. Chaudhary H, Kohli K, Kumar V. A novel nano-carrier transdermal gel against inflammation. Int J Pharm. 2014;465(1–2):175–86. doi:10.1016/j.ijpharm.2014.02.023.
95. Wang J, Wang H, Zhu R, Liu Q, Fei J, Wang S. Anti-inflammatory activity of curcumin-loaded solid lipid nanoparticles in IL-1beta transgenic mice subjected to the lipopolysaccharide-induced sepsis. Biomaterials. 2015;53:475–83. doi:10.1016/j.biomaterials.2015.02.116.
96. Gugulothu D, Kulkarni A, Patravale V, Dandekar P. pH-sensitive nanoparticles of curcumin-celecoxib combination: evaluating drug synergy in ulcerative colitis model. J Pharm Sci. 2014;103(2):687–96. doi:10.1002/jps.23828.
97. Singh N, Khullar N, Kakkar V, Kaur IP. Attenuation of carbon tetrachloride-induced hepatic injury with curcumin-loaded solid lipid nanoparticles. BioDrugs: Clin Immunotherapeutics Biopharm Gene Ther. 2014;28(3):297–312. doi:10.1007/s40259-014-0086-1.
98. Arora R, Kuhad A, Kaur IP, Chopra K. Curcumin loaded solid lipid nanoparticles ameliorate adjuvant-induced arthritis in rats. Eur J Pain. 2014. doi:10.1002/ejp.620.
99. Maradana MR, Thomas R, O’Sullivan BJ. Targeted delivery of curcumin for treating type 2 diabetes. Mol Nutr Food Res. 2013;57(9):1550–6. doi:10.1002/mnfr.201200791.
100. Joshi RP, Negi G, Kumar A, Pawar YB, Munjal B, Bansal AK, et al. SNEDDS curcumin formulation leads to enhanced protection from pain and functional deficits associated with diabetic neuropathy: an insight into its mechanism for neuroprotection. Nanomedicine. 2013;9(6):776–85. doi:10.1016/j.nano.2013.01.001.
101. Devadasu VR, Wadsworth RM, Kumar MN. Protective effects of nanoparticulate coenzyme Q10 and curcumin on inflammatory markers and lipid metabolism in streptozotocin-induced diabetic rats: a possible remedy to diabetic complications. Drug Deliv Transl Res. 2011;1(6):448–55. doi:10.1007/s13346-011-0041-3.
102. Yekollu SK, Thomas R, O’Sullivan B. Targeting curcusomes to inflammatory dendritic cells inhibits NF-kappaB and improves insulin resistance in obese mice. Diabetes. 2011;60(11):2928–38. doi:10.2337/db11-0275.
103. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23(1A):363–98.
104. Garbuzenko OB, Winkler J, Tomassone MS, Minko T. Biodegradable Janus nanoparticles for local pulmonary delivery of hydrophilic and hydrophobic molecules to the lungs. Langmuir: ACS J Surf Colloids. 2014;30(43):12941–9. doi:10.1021/la502144z.
105. Wang W, Zhu R, Xie Q, Li A, Xiao Y, Li K, et al. Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int J Nanomedicine. 2012;7:3667–77. doi:10.2147/IJN.S30428.
106. Yen FL, Tsai MH, Yang CM, Liang CJ, Lin CC, Chiang YC, et al. Curcumin nanoparticles ameliorate ICAM-1 expression in TNF-alpha-treated lung epithelial cells through p47 (phox) and MAPKs/AP-1 pathways. PLoS One. 2013;8(5), e63845. doi:10.1371/journal.pone.0063845.
107. Kumar A, Glaum M, El-Badri N, Mohapatra S, Haller E, Park S, et al. Initial observations of cell-mediated drug delivery to the deep lung. Cell Transplant. 2011;20(5):609–18. doi:10.3727/096368910X536491.
108. Selvam P, El-Sherbiny IM, Smyth HD. Swellable hydrogel particles for controlled release pulmonary administration using propellant-driven metered dose inhalers. J Aerosol Med Pulm Drug Deliv. 2011;24(1):25–34. doi:10.1089/jamp.2010.0830.
109. Ye Y, Li Y, Fang F. Upconversion nanoparticles conjugated with curcumin as a photosensitizer to inhibit methicillin-resistant Staphylococcus aureus in lung under near infrared light. Int J Nanomedicine. 2014;9:5157–65. doi:10.2147/IJN.S71365.
110. Moghadamtousi SZ, Kadir HA, Hassandarvish P, Tajik H, Abubakar S, Zandi K. A review on antibacterial, antiviral, and antifungal activity of curcumin. BioMed Res Int. 2014;2014:186864. doi:10.1155/2014/186864.
111. Akbik D, Ghadiri M, Chrzanowski W, Rohanizadeh R. Curcumin as a wound healing agent. Life Sci. 2014;116(1):1–7. doi:10.1016/j.lfs.2014.08.016.
112. Bhawana, Basniwal RK, Buttar HS, Jain VK, Jain N. Curcumin nanoparticles: preparation, characterization, and antimicrobial study. J Agric Food Chem. 2011;59(5):2056–61. doi:10.1021/jf104402t.
113. Dogra N, Choudhary R, Kohli P, Haddock JD, Makwana S, Horev B, et al. Polydiacetylene nanovesicles as carriers of natural phenylpropanoids for creating antimicrobial food-contact surfaces. J Agric Food Chem. 2015;63(9):2557–65. doi:10.1021/jf505442w.
114. Gong C, Wu Q, Wang Y, Zhang D, Luo F, Zhao X, et al. A biodegradable hydrogel system containing curcumin encapsulated in micelles for cutaneous wound healing. Biomaterials. 2013;34(27):6377–87. doi:10.1016/j.biomaterials.2013.05.005.
115. Krausz AE, Adler BL, Cabral V, Navati M, Doerner J, Charafeddine RA, et al. Curcumin-encapsulated nanoparticles as innovative antimicrobial and wound healing agent. Nanomedicine. 2015;11(1):195–206. doi:10.1016/j.nano.2014.09.004.
116. Said DE, Elsamad LM, Gohar YM. Validity of silver, chitosan, and curcumin nanoparticles as anti-Giardia agents. Parasitol Res. 2012;111(2):545–54. doi:10.1007/s00436-012-2866-1.
117. Pescosolido N, Giannotti R, Plateroti AM, Pascarella A, Nebbioso M. Curcumin: therapeutical potential in ophthalmology. Planta Med. 2014;80(4):249–54. doi:10.1055/s-0033-1351074.
118. Lou J, Hu W, Tian R, Zhang H, Jia Y, Zhang J, et al. Optimization and evaluation of a thermoresponsive ophthalmic in situ gel containing curcumin-loaded albumin nanoparticles. Int J Nanomedicine. 2014;9:2517–25. doi:10.2147/IJN.S60270.
119. Pradhan N, Guha R, Chowdhury S, Nandi S, Konar A, Hazra S. Curcumin nanoparticles inhibit corneal neovascularization. J Mol Med. 2015. doi:10.1007/s00109-015-1277-z.
120. Rachmawati H, Edityaningrum CA, Mauludin R. Molecular inclusion complex of curcumin-beta-cyclodextrin nanoparticle to enhance curcumin skin permeability from hydrophilic matrix gel. AAPS PharmSciTech. 2013;14(4):1303–12. doi:10.1208/s12249-013-0023-5.
121. Janesirisakule S, Sinthusake T, Wanichwecharungruang S. Nanocarrier with self-antioxidative property for stabilizing and delivering ascorbyl palmitate into skin. J Pharm Sci. 2013;102(8):2770–9. doi:10.1002/jps.23641.
122. Suwannateep N, Wanichwecharungruang S, Fluhr J, Patzelt A, Lademann J, Meinke MC. Comparison of two encapsulated curcumin particular systems contained in different formulations with regard to in vitro skin penetration. Skin Res Technol: Off J Int Soc Bioeng Skin. 2013;19(1):1–9. doi:10.1111/j.1600-0846.2011.00600.x.
123. Castangia I, Nácher A, Caddeo C, Valenti D, Fadda AM, Díez-Sales O, et al. Fabrication of quercetin and curcumin bionanovesicles for the prevention and rapid regeneration of full-thickness skin defects on mice. Acta Biomater. 2014;10(3):1292–300. doi:10.1016/j.actbio.2013.11.005.
124. Suwannateep N, Wanichwecharungruang S, Haag SF, Devahastin S, Groth N, Fluhr JW, et al. Encapsulated curcumin results in prolonged curcumin activity in vitro and radical scavenging activity ex vivo on skin after UVB-irradiation. Eur J Pharm Biopharmaceutics: Off J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2012;82(3):485–90. doi:10.1016/j.ejpb.2012.08.010.
125. Nayak AP, Tiyaboonchai W, Patankar S, Madhusudhan B, Souto EB. Curcuminoids-loaded lipid nanoparticles: novel approach towards malaria treatment. Colloids Surf B: Biointerfaces. 2010;81(1):263–73. doi:10.1016/j.colsurfb.2010.07.020.
126. Isacchi B, Bergonzi MC, Grazioso M, Righeschi C, Pietretti A, Severini C, et al. Artemisinin and artemisinin plus curcumin liposomal formulations: enhanced antimalarial efficacy against Plasmodium berghei-infected mice. Eur J Pharm Biopharm: Off J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2012;80(3):528–34. doi:10.1016/j.ejpb.2011.11.015.
127. Akhtar F, Rizvi MM, Kar SK. Oral delivery of curcumin bound to chitosan nanoparticles cured Plasmodium yoelii infected mice. Biotechnol Adv. 2012;30(1):310–20. doi:10.1016/j.biotechadv.2011.05.009.
128. Egan ME, Pearson M, Weiner SA, Rajendran V, Rubin D, Glockner-Pagel J, et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science. 2004;304(5670):600–2. doi:10.1126/science.1093941.
129. Lipecka J, Norez C, Bensalem N, Baudouin-Legros M, Planelles G, Becq F, et al. Rescue of DeltaF508-CFTR (cystic fibrosis transmembrane conductance regulator) by curcumin: involvement of the keratin 18 network. J Pharmacol Exp Ther. 2006;317(2):500–5. doi:10.1124/jpet.105.097667.
130. Cartiera MS, Ferreira EC, Caputo C, Egan ME, Caplan MJ, Saltzman WM. Partial correction of cystic fibrosis defects with PLGA nanoparticles encapsulating curcumin. Mol Pharm. 2010;7(1):86–93. doi:10.1021/mp900138a.
131. Heo DN, Ko WK, Moon HJ, Kim HJ, Lee SJ, Lee JB, et al. Inhibition of osteoclast differentiation by gold nanoparticles functionalized with cyclodextrin curcumin complexes. ACS Nano. 2014;8(12):12049–62. doi:10.1021/nn504329u.
132. Potter KA, Jorfi M, Householder KT, Foster EJ, Weder C, Capadona JR. Curcumin-releasing mechanically adaptive intracortical implants improve the proximal neuronal density and blood–brain barrier stability. Acta Biomater. 2014;10(5):2209–22. doi:10.1016/j.actbio.2014.01.018.
133. Sankar P, Telang AG, Kalaivanan R, Karunakaran V, Suresh S, Kesavan M. Oral nanoparticulate curcumin combating arsenic-induced oxidative damage in kidney and brain of rats. Toxicol Ind Health. 2013. doi:10.1177/0748233713498455.
134. Ahmad N, Warsi MH, Iqbal Z, Samim M, Ahmad FJ. Quantification of curcumin, demethoxycurcumin, and bisdemethoxycurcumin in rodent brain by UHPLC/ESI-Q-TOF-MS/MS after intra-nasal administration of curcuminoids loaded PNIPAM nanoparticles. Drug Test Anal. 2014;6(3):257–67. doi:10.1002/dta.1472.
135. Gandapu U, Chaitanya RK, Kishore G, Reddy RC, Kondapi AK. Curcumin-loaded apotransferrin nanoparticles provide efficient cellular uptake and effectively inhibit HIV-1 replication in vitro. PLoS One. 2011;6(8), e23388. doi:10.1371/journal.pone.0023388.